PCI Biotech Holding ASA Oslo, Norway, 25 February 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's full-year 2024 interim report on Thursday 27 February 2025, 08 ...
Briquilimab demonstrates rapid, clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study ​ Abstract Number: S040 Session ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug ...
Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in ...
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. Vir ...
Oslo, Norway, 25 February 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's full-year 2024 interim report on Thursday 27 February 2025, 08:30am – 09:00am CET (local ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results